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An R-Type Ca21 Current in Neurohypophysial Terminals
Preferentially Regulates Oxytocin Secretion
Gang Wang,1 Govindan Dayanithi,2 Robert Newcomb,3 and Jose´ R. Lemos1
1Department of Physiology and Neuroscience Program, University of Massachusetts Medical School, Worcester,
Massachusetts 01655, 2UPR9055-CNRS, Biologie des Neurones Endocrines, Montpellier, Cedex 5, France, and 3Elan
Pharmaceuticals, Menlo Park, California 94025
Multiple types of voltage-dependent Ca21 channels are in-
volved in the regulation of neurotransmitter release (Tsien et al.,
1991; Dunlap et al., 1995). In the nerve terminals of the neuro-
hypophysis, the roles of L-, N-, and P/Q-type Ca21 channels in
neuropeptide release have been identified previously (Wang et
al., 1997a). Although the L- and N-type Ca21 currents play
equivalent roles in both vasopressin and oxytocin release, the
P/Q-type Ca21 current only regulates vasopressin release. An
oxytocin-release and Ca21 current component is resistant to
the L-, N-, and P/Q-type Ca21 channel blockers but is inhibited
by Ni21. A new polypeptide toxin, SNX-482, which is a specific
a1E-type Ca
21 channel blocker (Newcomb et al., 1998), was
used to characterize the biophysical properties of this resistant
Ca21 current component and its role in neuropeptide release.
This resistant component was dose dependently inhibited by
SNX-482, with an IC50 of 4.1 nM. Furthermore, SNX-482 did not
affect the other Ca21 current types in these CNS terminals. Like
the N- and P/Q-type Ca21 currents, this SNX-482-sensitive
transient Ca21 current is high-threshold activated and shows
moderate steady-state inactivation. At the same concentra-
tions, SNX-482 blocked the component of oxytocin, but not of
vasopressin, release that was resistant to the other channel
blockers, indicating a preferential role for this type of Ca21
current in oxytocin release from neurohypophysial terminals.
Our results suggest that an a1E or “R”-type Ca
21 channel exists
in oxytocinergic nerve terminals and, thus, functions in control-
ling only oxytocin release from the rat neurohypophysis.
Key words: class E (a1E ) Ca
21 channel; secretion; SNX-482;
vasopressin; posterior pituitary; oxytocin
Voltage-dependent channels are responsible for the Ca21 that
enters nerve terminals and elicits vesicular release of neurotrans-
mitters (Augustine et al., 1987). Neurotransmitter release in the
CNS is regulated by multiple types of Ca21 channels (Dunlap et
al., 1995). A number of studies have defined several electrophysi-
ologically distinct Ca21 channels on neuronal cell bodies: L-, N-,
T-, and P-types (Fox et al., 1987; Bean, 1989; Tsien et al., 1991;
Llinas et al., 1992). Other classes of channels, such as the Q- and
R-types, have been revealed by molecular cloning (Snutch and
Reiner, 1992; Ellinor et al., 1993; Sather et al., 1993; Perez-Reyes
et al., 1998) and the use of Ca21 antagonists (Olivera et al., 1984;
Hillyard et al., 1992; Ramachandran et al., 1993; Newcomb et al.,
1998). The specific role at CNS terminals of these different types
of Ca21 channels, however, is still unclear.
The N-type channel seems to be involved in classical neuro-
transmission (Hirning et al., 1988), whereas the L-type is known
to regulate the secretion of certain peptides (Cazalis et al., 1987;
Dunlap et al., 1995). The class E (a1E) and G (a1G) Ca
21
channels have been localized recently to the CNS (Westenbroek
et al., 1995; Perez-Reyes et al., 1998). However, the phenotype of
the expressed a1E channel is controversial (Snutch and Reiner,
1992; Randall and Tsien, 1995), and the biophysical properties of
the class E current in CNS terminals remain to be determined.
To determine any role for class E channels in CNS secretion
(see Wu et al., 1998, 1999), we studied the nerve terminals of the
rat neurohypophysis. This is a population of relatively homoge-
neous peptidergic nerve endings that allows comparative study by
a number of different techniques. This has been a very useful
model system for characterization of nerve terminal Ca 21 chan-
nels (Lemos and Nowycky, 1989; Wang et al., 1992, 1997a; Wang
and Lemos, 1994; Fisher and Bourque, 1995) and of mechanisms
underlying depolarization–secretion coupling (Cazalis et al.,
1987; Lim et al., 1990; Lindau et al., 1992; Wang et al., 1993b,
1997a; Branchaw et al., 1998). We have shown previously that
“L”- and “N”-type Ca21 channels exist in nerve terminals of the
neurohypophysis (Lemos and Nowycky, 1989; Wang et al., 1992)
and that they control both vasopressin (AVP) and oxytocin (OT)
release, except for a significant resistant component (Cazalis et
al., 1987; Dayanithi et al., 1988; Wang et al., 1993b). More
recently we have shown that a “Q”-type Ca 21 current component
also exists in approximately one-half of these CNS terminals
(Wang et al., 1997a). Moreover, when blockers of the Q-type
Ca21 current were added to the terminals, the resistant compo-
nent of AVP release was essentially abolished. In contrast, a
similar resistant component of OT release was unchanged by the
same concentrations of the Q-type channel blockers.
Most recently we have shown that purified native SNX-482, a
specific a1E channel blocker, could inhibit the neurohypophysial
Ca21 current (Newcomb et al., 1998). This led us to examine,
Received May 10, 1999; revised Aug. 16, 1999; accepted Aug. 18, 1999.
We would like to acknowledge support by the National Institutes of Health Grant
NS29470 (J.R.L.). Portions of this work were supported by the Neurex Pharmaceu-
tical Corporation, and we would like to thank members of their synthetic chemistry
group for providing the synthetic peptides. We also thank G. Miljanich for support
and advice.
Correspondence should be addressed to Dr. Jose´ R. Lemos, Department of Phys-
iology and Neuroscience Program, University of Massachusetts Medical School, 55
Lake Avenue North, Worcester, MA 01655. E-mail: Jose.Lemos@umassmed.edu.
Dr. Wang’s present address: Division of Neurobiology, Department of Neurology
and Neuroscience, Cornell University Medical College, 411 East 69th Street, New
York, NY 10021.
Copyright © 1999 Society for Neuroscience 0270-6474/99/199235-07$05.00/0
The Journal of Neuroscience, November 1, 1999, 19(21):9235–9241
using a combination of pharmacological and biophysical tech-
niques, whether class E or R-type Ca21 channels might also exist
on these CNS terminals and functionally contribute to
neurosecretion.
MATERIALS AND METHODS
Electrophysiolog ical recordings. As we have described previously (Wang et
al., 1997a), after sedation by CO2 the rats were killed by decapitation
using a guillotine. The neurohypophysis was then excised, following
previous protocols, and homogenized in a solution containing (in mM):
sucrose, 270; HEPES-Tris, 10; and K-EGTA, 0.01, pH 7.25 (Cazalis et
al., 1987). All chemicals were obtained from Sigma (St. Louis, MO). The
isolated neurohypophysial nerve terminals could be identified under an
inverted microscope (Nordmann et al., 1987). Normal Locke’s solution
[containing (in mM), NaCl, 145; KCl, 5; CaCl2, 2.2; MgCl2, 1; Na-
HEPES, 10; and glucose, 15, pH 7.35] was then used to perfuse the
terminals. Before patch-clamp recordings, the terminals (usually 5–8 mm
in diameter) were perfused with the 5 mM Ba 21 (replacing CaCl2)
Locke’s solution, which also contained 1 mM TTX with 0.02% BSA. To
obtain perforated-patch (Rae et al., 1991) recordings in the “whole-
terminal” configuration (Hamill et al., 1981), freshly made amphotericin
B (240 –300 mg/ml) was mixed with the pipette solution that contained (in
mM): Cs-glutamate, 135; HEPES, 10; glucose, 5; CaCl2, 2; MgCl2, 1; and
TEA, 20, pH 7.25.
As reported previously (Wang et al., 1997a), the perforated-patch
recording configuration enables us to overcome problems with the run-
down of Ca 21 currents that complicated former studies (Lemos and
Nowycky, 1989; Wang et al., 1992; Wang and Lemos, 1994; Fisher and
Bourque, 1995; Branchaw et al., 1998). Only terminals with perforated-
patch access resistances of ,10 MV were chosen for further recordings.
The Ba 21 current (IBa), which was activated by depolarizing from 280 to
110 mV and demonstrated both transient and long-lasting components
(see, e.g., Fig. 1A), could be maintained for .1 hr without appreciable
rundown. The IBa was filtered at 3 kHz and sampled at 10 kHz. pClamp
(Axon Instruments, Burlingame, CA) was used for acquisition and anal-
ysis of data.
Peptide release. Rat neurohypophyses (see Electrophysiological record-
ings) were homogenized as described previously (Cazalis et al., 1987).
The homogenate was centrifuged at 2400 3 g for 6 min. The resulting
pellet contains highly purified nerve terminals. The nerve endings were
loaded onto filters (0.45 mm Acro disk; Gelman Sciences, Ann Arbor,
MI) and perfused at 37°C with normal Locke’s solution. Four minute
fractions of perfusate were collected, and the evoked release was trig-
gered by an 8-min-duration pulse of a depolarizing concentration (50
mM) of K 1. The results are given as AVP or OT release per fraction
using specific radioimmunoassays (Wang et al., 1997a). The medium
before and after the depolarizing period contained (in mM): NaCl, 40;
KHCO3, 5; N-methyl-D-glucamine (NMG)-Cl, 100; MgCl2, 1; CaCl2, 2;
glucose, 10; and Tris-HEPES, 10, with 0.02% BSA, pH 7.25. Depolar-
ization medium contained 50 mM K 1, in which the NMG was reduced to
maintain the osmolarity (300–310 mOsm).
Polypeptide toxins. The polypeptide toxins used in this study were
synthetic versions prepared by Neurex Pharmaceutical Corporation (Ra-
machandran et al., 1993). These were termed SNX-482, the synthetic
version of a novel 41 amino acid peptide isolated from the venom of the
West African tarantula Hysterocrates g igas (Newcomb et al., 1998), SNX-
111, the synthetic version of v-conopeptide MVIIA (Olivera et al.,
1994), SNX-194, the methionine-12 to norleucin-12 derivative of SNX-
111, and SNX-230, the synthetic version of MVIIC (Hillyard et al.,
1992). The synthetic version of v-AgaIVA (Mintz et al., 1992) was
purchased from Peptides International (Louisville, KY) or synthesized
as described by Gaur et al., (1994). In the text we refer to the synthetic
peptides by their original names or by the Neurex terms.
Data analysis. All results are given as means 6 SEM, and the statistical
significance of differences in groups was analyzed using SigmaStat (Jan-
del Scientific, San Rafael, CA) with Tukey’s t tests.
RESULTS
Ca21 channel currents
In the isolated neurohypophysial terminals, the peak IBa, which
was activated by depolarizing from 280 to 110 mV, demon-
strates both transient and long-lasting components (Fig. 1A). As
we have reported previously (Wang et al., 1997a), the use of the
dihydropyridine (DHP) Ca21 channel antagonist nicardipine (2.5
mM) selectively inhibits the long-lasting (L-) component of the
Ba21 currents (Fig. 1). Subsequent addition of the N-type Ca21
channel blocker MVIIA (3000 nM) led to rapid inhibition of a
large portion of the isolated transient component (and, to a lesser
extent, the long-lasting component) of the Ba21 current. This
concentration has been shown previously to block the N-type
component maximally (Wang et al., 1997a).
In ;50% of the neurohypophysial terminals investigated, sub-
sequent addition of low (36 nM) concentrations of MVIIC inhib-
ited this remaining component, and higher (150 nM) concentra-
tions almost completely abolished it (Wang et al., 1997a). In
another group of terminals (;46%), however, the non-L- and
-N-types of Ca 21 currents could not be blocked by the P/Q-type
Ca21 channel blockers MVIIC or AgaIVA (Fig. 1). This resis-
tant part of the transient Ca21 current appeared to be analogous
to an R-type Ca21 channel current (Randall and Tsien, 1995).
Pharmacology of resistant Ca21 channel currents
To test whether this resistant component of the Ba 21 current
could indeed be classified as an R-type Ca21 channel current,
Ni21, a T- and R-type Ca 21 channel blocker, was applied to this
terminal. Low concentrations (86mM) of Ni21 inhibited the resis-
tant current (Fig. 1). Because of the low selectivity of Ni21
between Ca21 channels, however, the identity of the resistant
component of the Ca 21 current in the nerve terminal was still
unclear.
A newly discovered polypeptide toxin, SNX-482, was found to
be a specific blocker of the class E (a1E) Ca
21 channel (Newcomb
et al., 1998). This toxin made it possible for us to identify the
Ni21-sensitive type of Ca21 current and to probe its function in
neurohypophysial nerve terminals (Wang et al., 1997b; Dayanithi
et al., 1999).
Figure 1. A toxin-resistant Ba 21 current in neurohypophysial terminals
is blocked by Ni 21. Subtypes of the macroscopic Ba 21 current (IBa ) in
nerve terminals can be pharmacologically dissected by applying different
Ca 21 channel blockers. A, In an isolated rat neurohypophysial terminal,
the IBa was elicited by depolarizations (see template above) and first
recorded under control conditions (5 mM Ba 21 Locke’s solution) and then
after subsequent applications (shown by horizontal bars in B) of the
L-type blocker nicardipine (2.5 mM), the N-type Ca 21 channel blocker
MVIIA (3 mM), and the P/Q-type blockers MVIIC (100 nM) and AgaIVA
(450 nM). There was a resistant Ba 21 current component that could only
be dose dependently (86–258 mM) inhibited by Ni 21. B, The correspond-
ing time–response plot of the peak values of the macroscopic IBa is shown.
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First, the effects of SNX-482 on the long-lasting and transient
components of the Ba21 current of the neurohypophysial termi-
nals were examined (Fig. 2A). The isolated, transient component
of the Ba21 current usually includes an N-type and either a
P/Q-type or a resistant component of Ca21 channel currents
(Wang et al., 1997a). The IC50 for the undifferentiated transient
IBa, obtained from the equation I 5 Imax{1 2 [x/(IC50 1 x)]}, is
226 nM (Fig. 2B). This is similar to that for SNX-482 to inhibit the
cloned a1B (N-type) Ca
21 channel current but much higher than
that (IC50 5 10 nM) to block the heterologously expressed a1E-
type currents (Newcomb et al., 1998). The toxin does not affect
the DHP-sensitive or L-type current in these terminals. These
results indicate that, at high concentrations, SNX-482 could block
some combination of N-, P/Q-, and/or class E-type Ca21 chan-
nels in the terminals.
Application of a combination of DHP, MVIIA, and MVIIC or
of high concentrations of MVIIA/SNX-194 and MVIIC/
AgaIVA allowed us to obtain isolated “resistant” Ba21 or Ca21
currents (Fig. 3A). SNX-482, in a dose-dependent manner (in a
total of seven terminals), inhibited the isolated resistant currents
(Fig. 3A,B) with an IC50 of 4.1 nM (Fig. 3C), similar to that found
for the a1E Ca
21 currents expressed in human embryonic kidney
(HEK) cells (Newcomb et al., 1998). The inhibition by SNX-482
of the resistant-type Ba21 current is reversible (Fig. 3D). Fur-
thermore, both SNX-482 and Ni21 inhibited the same previously
resistant component of the Ba21 current (Fig. 3D).
Any sensitivity of P/Q-type currents in the nerve terminals to
SNX-482 was then examined. As shown in Figure 4A, in the
presence of the L-type blocker nicardipine and the N-type
blocker MVIIA, the remaining Ba21 component was not affected
by SNX-482, although it was inhibited by the P/Q-type blocker
AgaIVA. This confirmed that SNX-482 is not a P/Q-type or class
A channel blocker (Newcomb et al., 1998). The inhibition of the
resistant Ba21 current component, in ;46% of the neurohypo-
physial terminals investigated, by both Ni21 and SNX-482 lead us
to conclude that this channel current most closely resembles that
of the a1E Ca
21 channel subunit expressed in HEK cells (New-
comb et al., 1998).
Interestingly, in ;5% of the terminals investigated (n 5 21), in
addition to the L- and N-type Ca 21 channel currents, there
appears to exist both P/Q- and SNX-482-sensitive-type Ba21
Figure 3. SNX-482 blocks the previ-
ously resistant neurohypophysial IBa.
The IBa was elicited by depolarizations
to 0 mV. A, Representative traces of
resistant macroscopic IBa inhibited by
SNX-482 in a dose-dependent manner
after an application of high concentra-
tions of SNX-194 (3 mM) and MVIIC (2
mM) to block the other components. B,
The I–V relation of the macroscopic IBa
under control conditions (E) and in the
presence of SNX-194 and MVIIC (F)
and 3 nM (), 6 nM (), and 24 nM (M)
SNX-482. C, The dose–response curve
of the effects of SNX-482 on the isolated
resistant IBa in neurohypophysial termi-
nals. The dotted line fit was obtained
from the equation I 5 Imax{1 2 [x/(IC50
1 x)]}. D, Reversibility of the effects of
SNX-482 and Ni 21 on the isolated re-
sistant (to nicardipine 1 MVIIA 1
MVIIC) IBa. Ni
21 and SNX-482 appear
to inhibit the same component of the
current.
Figure 2. SNX-482 inhibits only the transient IBa in nerve terminals.
Dose-dependent inhibition by SNX-482 of the total macroscopic IBa of
neurohypophysial terminals is shown. A, A representative time–response
plot (see, e.g., Fig. 1B) of the effect of 1–30 nM SNX-482 on the total
macroscopic IBa current. Note that the remaining current in the nerve
terminal was sensitive to MVIIA and nicardipine. B, Dose–response
curve for the effect of SNX-482 on the undifferentiated transient macro-
scopic IBa (n 5 3). The solid line was obtained from fitting with the
equation I 5 Imax{1 2 [x/(IC50 1 x)]}, where I is the current amplitude at
a given voltage, Imax is the maximum current, and x is the blocker’s
concentration. ctrl, Control.
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currents. Figure 4B is an example of this, showing that the non-L-
and non-N-type Ba21 currents were partially sensitive to both
SNX-482 and AgaIVA.
Biophysical properties
Biophysical characterization of the resistant component of the
neurohypophysial terminal IBa also favors a class E or R-type
Ca21 channel classification. This component of the current is a
transient, high-voltage-activated Ba21 current with an inactiva-
tion rate constant of 21 6 3 msec (n 5 7) during a step to 0 mV
(see Fig. 3A). Figure 5A illustrates the activation (V1/2 5 214.2
mV) and steady-state inactivation (V1/2 5 258.8 mV) of the
SNX-482-sensitive component of the neurohypophysial terminal
Ba21 current. The inactivating rate constant and activation and
steady-state inactivation curves (Fig. 5A) of this neurohypophy-
sial Ca21 current component are most consistent with those of
the R-type Ca21 channel in granule cells (Randall and Tsien,
1995). Nevertheless, the other transient Ca21 current compo-
nents (N- and P/Q-type) appear to have biophysical properties
similar to those of this “R”-type Ca 21 component (Wang et al.,
1997a).
The relative permeabilities for Ca 21 versus Ba 21 between the
total channel currents and the isolated SNX-482-sensitive or
R-type current were compared, as shown in Figure 5B. Ba 21
currents were significantly larger than the corresponding Ca21
currents for both the total and the isolated components. The
inactivation rate constant, however, differed. The total current
showed slower inactivation with Ba21 as compared with Ca21 as
the charge carrier, whereas the R-type currents showed no dif-
ference in their inactivation with either Ba21 or Ca21.
Peptide release
In a previous report (Wang et al., 1997a), we found that a
significant portion of OT release could not be inhibited even by
simultaneous applications of L-, N-, and P/Q-type Ca 21 channel
blockers. To determine whether the class E or R-type Ca21
channel could play a role in this secretion, we measured both OT
and AVP release in the same samples collected from perfused
populations of nerve terminals (Fig. 6). Capitalizing on the same
pharmacological protocol used to isolate the R-type component
electrophysiologically (see Fig. 3A), we revealed a similar resis-
tant component (42.3%) of Ca21-dependent OT release (Fig.
6B). In these experiments, high K1 alone induced OT release of
4258 6 306 pg (n 5 4), and both nicardipine and MVIIA, given
in combination, reduced (by 57.7 6 3.8%) high-K1-stimulated
release to 1812 6 376 pg. SNX-482 (20 nM) completely blocked
the remaining stimulated OT release (to basal level, 159 6 33 pg).
In contrast, a similar resistant component (38.4%) of stimulated
AVP release (406 6 30 pg) was essentially unchanged (458 6 63
pg; n 5 4) by the same concentration of this R-type channel
blocker (Fig. 6A). As shown previously (Wang et al., 1997a), this
resistant component of AVP release was blocked (to basal level,
60 6 3 pg) by the P/Q-type blocker MVIIC. These results were
the same even if the order of drugs was reversed or scrambled
(data not shown). Furthermore, stimulated release was stable
during prolonged applications of each of the Ca 21 channel block-
ers, indicating that steady-state effects had been established.
We have also performed a set of experiments to compare
quantitatively the SNX- 482 block of OT release with the IC50 of
this toxin on R-type calcium channels. As described in the Figure
6 legend, the nerve terminals were challenged with 50 mM K1
either in the absence of any channel blocker (control) or in the
presence of both 2.5 mM nicardipine (L-type channel blocker) and
1 mM MVIIA (N-type channel blocker) and then subsequently
with varying concentrations of SNX-482 (1, 5, 10, 20, 50, or 100
nM). In this batch of experiments, K1 alone evoked 3678 6 139
Figure 4. SNX-482 does not block the neurohypophysial P/Q-type Ca 21
current. A, A representative time–response curve of the peak values of
the macroscopic IBa of an isolated nerve terminal insensitive to SNX-482
is shown. The IBa was recorded under control conditions and after
subsequent applications of the L-type Ca 21 channel blocker nicardipine
(2.5 mM) and the N-type Ca 21 channel blocker MVIIA (4 mM). SNX-482
(40 nM) did not affect the remaining Ba 21 current, which was subse-
quently blocked by the P/Q-type blocker AgaIVA (450 nM). B, By the use
of the same protocol described in A, SNX-482 and AgaIVA each had a
partial effect on the non-L and non-N-type Ba 21 current in a different
nerve terminal. Therefore, some (;5%) neurohypophysial terminals have
both P/Q- and R-type currents.
Figure 5. Voltage dependence and kinetics of Ba 21 and Ca 21 currents
in neurohypophysial terminals. A, Activation (F) and steady-state inacti-
vation (E) curves for the pharmacologically isolated (see Fig. 1) R-type
macroscopic Ba 21 currents are illustrated (n 5 3). The peak Ba 21
currents elicited were normalized to the maximal currents (for the steady-
state inactivation curve) or conductances (for the activation curve) and
plotted versus the holding potentials or the step potentials, respectively.
Data for activation and steady-state inactivation were fit using appropri-
ate forms of the Boltzmann equation. For activation, C 5 Cmax{1 1
exp[(V1/2 2 Vs)/k]}
21, and for steady-state inactivation, I 5 Imax{1 1
exp[(V
s
2 V1/2 )/k]}
21, where C is the conductance at a given voltage, Cmax
is the maximum conductance, I is the current amplitude at a given
voltage, Imax is the maximum current, Vs is the voltage step, V1/2 is the
midpoint potential, and k is the slope parameter. The fitting of the two
curves for the isolated resistant (R)-type IBa gives V1/2 values of 214.1
mV (k 5 5.0) and 258.8 mV (k 5 5.7) for activation and inactivation,
respectively. B, Comparison of amplitudes and inactivation rates of the
total versus R-type Ca 21 and Ba 21 currents is shown. Bottom histograms,
The 5 mM Ba 21 total currents (n 5 5) and the isolated R-type Ba 21
currents (n 5 4) were larger than the 5 mM Ca 21 total currents (n 5 5)
and isolated R-type Ca 21 currents (n 5 3), respectively ( p , 0.01). Top
histograms, The inactivation time constant (t) was obtained from the same
groups of terminals (as above). The 5 mM Ba 21 total currents had larger
t values, or slower inactivation, than did the 5 mM Ca 21 current group
( p , 0.01). The R-type Ba 21 currents, however, had t values similar to
those of the R-type Ca 21 currents ( p . 0.05).
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pg (n 5 3). L- and N-type channel blockers reduced this OT
release by 59.7% (to 2194 6 100 pg). Further addition of 1, 5, 10,
20, 50, or 100 nM SNX-482 suppressed the resistant OT release by
8% (to 2018 6 30 pg), 32.6% (to 1478 6 54 pg), 61.4% (to 846 6
40 pg), 93.4% (to 145 6 7 pg), 95.6% (to 96 6 6 pg), and 97.6%
(to 52 6 6 pg), respectively. The IC50 calculated from the equa-
tion r 5 Rmax{1 2 [x/(IC50 1 x)]} for the SNX-482 block of OT
release is 6.8 nM, which is comparable with the IC50 for the toxin
on R-type calcium currents. Finally, the effects of SNX-482 on
OT versus AVP release were significantly ( p , .001) different,
thus revealing the importance of the class E or R-type component
in only OT release.
DISCUSSION
The isolated neurohypophysial terminals are uniquely useful for
studying the pharmacological, biophysical, and functional prop-
erties of Ca21 channels at the site of secretion, and they have
revealed a surprising pharmacological and functional complexity
in the CNS presynaptic Ca21 channel family.
Four different components of Ca21-dependent
neuropeptide release
The regulation of neurotransmission in the mammalian CNS has
been characterized by the involvement of multiple types of
voltage-dependent Ca21 channels, each of which might play a
specific role in the regulation of neurotransmission. In the mam-
malian neurohypophysial system, the L- and N-type Ca21 chan-
nels play an equivalent role in both AVP and OT release. This is
quite different from the role of Ca 21 channels in classical neu-
rotransmission, in which the N- and P/Q-type, instead of the
L-type, Ca21 channel current are dominant in controlling neu-
rotransmitter release (Hirning et al., 1988; Wheeler et al., 1994;
Dunlap et al., 1995). Furthermore, the P/Q-type Ca 21 channel
has turned out to be critical for AVP release from neurohypo-
physial nerve terminals (Wang et al., 1997a). Finally, the present
results have demonstrated that an SNX-482-sensitive Ca21 cur-
rent is responsible for an important part of OT release.
Identity of the resistant Ca21 channel in
nerve terminals
We have now shown that the SNX-482-sensitive Ca21 current
has similar biophysical properties to that of the class E channel.
The phenotype of the expressed class E channel (Zhang et al.,
1993) can resemble that of native currents described as either R-
(Randall and Tsien, 1995) or T-type (Snutch and Reiner, 1992).
The T-type Ca21 channel in the CNS is a low-voltage-activated
channel that is affected by Ni21 (Tsien et al., 1991; Fisher and
Bourque, 1996). The terminal SNX-482-sensitive Ca 21 current,
although also blocked by Ni21, is moderately high voltage acti-
vated and more permeable to Ba 21 than to Ca 21 (Fig. 5B). Thus,
in terms of its biophysical properties, this channel appears to be
different from the T-type Ca21 channel.
A correspondence between cloned expressed class E calcium
channels and various currents described as resistant, or R-type, is
suggested by similar electrophysiological properties and resis-
tance to selective antagonists of N, P/Q, and L-type calcium
channels (Newcomb et al., 1998). In the absence of a selective
antagonist of the class E calcium channel, however, the corre-
spondence between calcium channel classes defined by cDNA
sequencing and electrophysiology has been unclear, and the role
of class E calcium channels in physiology has not been studied
previously (but see Wu et al., 1998, 1999). Our study capitalizes
on the recent discovery of a selective class E antagonist from
tarantula venom, SNX-482, and it has allowed us to analyze
directly the identity, function, and pharmacology of the resistant-
type calcium channels in CNS terminals.
The initial studies of the in vitro actions of native SNX-482 have
revealed unanticipated diversity in the response of native R-type
currents to the peptide (Newcomb et al., 1998). Nevertheless,
because low nanomolar concentrations of SNX-482 have no ef-
fects on other calcium channel subtypes (see Figs. 2, 4) (Newcomb
et al., 1998), the potent block of the neurohypophysial R-type
current demonstrates that the resistant current isolated pharma-
cologically is not simply residual current flowing through incom-
pletely blocked N-, P/Q-, and L-type calcium channels. Thus, the
Figure 6. Effects of the Ca 21 channel blocker SNX-482 on AVP versus
OT release from nerve terminals. A, AVP release was repeatedly stimu-
lated (see arrows) with 50 mM K 1. The isolated neurohypophysial termi-
nals were challenged with elevated K 1 either in the absence ( first arrow)
of any channel blockers or in the presence of 2.5 mM nicardipine (L-type
Ca 21 channel blocker) and 1 mM MVIIA (N-type Ca 21 channel blocker)
and then subsequently with the addition of 20 nM SNX-482 (R-type Ca 21
channel blocker) and finally plus 300 nM MVIIC (P/Q-type Ca 21 channel
blocker). All these drugs were present for at least 20 min before, during,
and after the K 1 stimulation (see differently shaded horizontal bars above).
The inhibitions were mostly reversible, as indicated by control K 1 stim-
ulation after washout (last arrow). All data points represent the mean of
four to six experiments. B, OT release was repeatedly stimulated with 50
mM K 1. The nerve terminals were challenged with elevated K 1 either in
the absence ( first arrow) of any channel blockers or in the presence of 2.5
mM nicardipine (L) and 1 mM MVIIA (N), then 20 nM SNX-482 (R), and
finally 300 nM MVIIC (P/Q) (see horizontal bars above). This inhibition
was also mostly reversible (last arrow). Note that the same perfusate
samples were assayed for both OT and AVP.
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variability of the response of native R-type currents almost cer-
tainly indicates pharmacological heterogeneity of the distinct
entities, perhaps splice variants, which are responsible for these
currents.
These variants could also explain the fact that class E mRNA
has, so far, not been detected in the hypothalamic magnocellular
somata that project to the neurohypophysis (Gainer and Chin,
1998). In contrast, preliminary evidence (G. Dayanithi, unpub-
lished results), using antibodies raised against class E channels,
has localized these channels to isolated neurohypophysial
terminals.
The R-type Ca21 channel controls OT, but not
AVP, release
Our data suggest that in one group of terminals, there is a Ni21-
and SNX-482-sensitive Ca21 channel able to regulate OT release
preferentially, whereas in another group of terminals the P/Q-
type Ca21 channel plays a converse role in AVP release. We
demonstrate here that the a1E class or R-type Ca
21 channel
exists on these neurohypophysial terminals, where it participates
in the control of neuropeptide secretion. These results lead to the
hypothesis that the R-type channels are preferentially localized
on OT peptide-containing nerve terminals and thus do not affect
Ca21 currents in vasopressinergic terminals. Interestingly, some
(5%) terminals appear to have both types of channels (Fig. 4B),
comparable with the observed percentage of terminals containing
both OT and AVP (Wang et al., 1997b). In any case, the data
clearly show that the R-type component plays an important role
in OT, but not in AVP, secretion from these CNS terminals.
In conclusion, we have demonstrated that an R-type Ca 21
channel exists in at least one type of CNS terminal and is
important in depolarization–secretion coupling. This lends sup-
port to the idea that R-type channels may play a specific role in
synaptic transmission in other CNS synapses (Newcomb et al.,
1998; Wu et al., 1998, 1999). The data presented here clarify the
specific identities and functional importance of the Ca21 chan-
nels actually located at nerve terminals and point out that the R-
and P/Q-channels, at least, may be heterogeneously localized for
different functions.
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